Razi Cov Pars (Catalan Wikipedia)

Analysis of information sources in references of the Wikipedia article "Razi Cov Pars" in Catalan language version.

refsWebsite

Global rank Catalan rank

3tehrantimes.com

4,540^th place

low place

low place

low place

2web.archive.org

1^st place

1^st place

754^th place

4,489^th place

422^nd place

low place

aa.com.tr

«Iran unveils second homegrown COVID-19 vaccine». Anadolu Agency, 07-02-2021 [Consulta: 22 abril 2021].

irct.ir

en.irct.ir

«Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial». Iranian Registry of Clinical Trials. Arxivat de l'original el 25 de maig 2021. [Consulta: 22 abril 2021].
«IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial». Arxivat de l'original el 2021-08-30. [Consulta: 30 agost 2021].

irct.ir

«Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial». Iranian Registry of Clinical Trials. [Consulta: 21 març 2021].

isna.ir

«مجوز مصرف اضطراری داوطلبانه واکسن کووپارس صبح امروز صادر شد» (en persa), 31-10-2021. [Consulta: 27 novembre 2021].

tehrantimes.com

«COVID-19 vaccine Razi Cov Pars starts third clinical trial phase» (en anglès), 27-08-2021. [Consulta: 30 agost 2021].
«Two homegrown vaccines receive emergency use license» (en anglès), 01-11-2021. [Consulta: 27 novembre 2021].
«Two homegrown vaccines receive emergency use license», 01-11-2021. [Consulta: 27 novembre 2021].

web.archive.org

«Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial». Iranian Registry of Clinical Trials. Arxivat de l'original el 25 de maig 2021. [Consulta: 22 abril 2021].
«IRCT | Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial». Arxivat de l'original el 2021-08-30. [Consulta: 30 agost 2021].